Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner

Neuropharmacology

Volumn 61, Issue 1-2, 2011, Pages 262-267

  Nikiforuk, Agnieszka ^a   Kos, Tomasz ^a   Rafa, Dominik ^a   Behl, Berthold ^b   Bespalov, Anton ^b   Popik, Piotr ^a,c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b ABBOTT GMBH AND CO KG   (Germany)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Attentional set shifting; Cognitive flexibility; Glycine; GlyT1 inhibitor; Prefrontal cortex

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; 3 AMINO 1 HYDROXY 4 METHYL 2 PYRROLIDINONE; GLYCINE; GLYCINE TRANSPORTER 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TASK PERFORMANCE;

ANIMALS; BENZAMIDES; COGNITION; DISCRIMINATION LEARNING; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; PIPERIDINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 79957791056     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.04.010     Document Type: Article

References (54)

1. Birrell, J.M., Brown, V.J., 2000. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20, 4320-4324. (Pubitemid 30365702)
2. Black, M.D., Varty, G.B., Arad, M., Barak, S., De Levie, A., Boulay, D., Pichat, P., Griebel, G., Weiner, I., 2009. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202, 385-396.
3. Boulay, D., Pichat, P., Dargazanli, G., Estenne-Bouhtou, G., Terranova, J.P., Rogacki, N., Stemmelin, J., Coste, A., Lanneau, C., Desvignes, C., Cohen, C., Alonso, R., Vige, X., Biton, B., Steinberg, R., Sevrin, M., Oury-Donat, F., George, P., Bergis, O., Griebel, G., Avenet, P., Scatton, B., 2008. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol. Biochem. Behav. 91, 47-58.
4. Broberg, B.V., Glenthoj, B.Y., Dias, R., Larsen, D.B., Olsen, C.K., 2009. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia-sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl.) 206, 631-640.
5. Coyle, J.T., Tsai, G., Goff, D., 2003. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. N. Y. Acad. Sci. 1003, 318-327.
6. Cubelos, B., Gimenez, C., Zafra, F., 2005. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb. Cortex 15, 448-459. (Pubitemid 40388245)
7. Danysz, W., Parsons, C.G., 1998. Glycine and NMDA receptors - physiological significance and possible therapeutic applications. Pharmacol. Rev. 50, 597-664.
8. Danysz, W., Parsons, C.G., Karczkubicha, M., Schwaier, A., Popik, P., Wedzony, K., Lazarewicz, J., Quack, G., 1998. GlycineB antagonists as potential therapeutic agents - previous hopes and present reality. Amino Acids 14, 235-239.
9. Depoortere, R., Dargazanli, G., Estenne-Bouhtou, G., Coste, A., Lanneau, C., Desvignes, C., Poncelet, M., Heaulme, M., Santucci, V., Decobert, M., Cudennec, A., Voltz, C., Boulay, D., Terranova, J.P., Stemmelin, J., Roger, P., Marabout, B., Sevrin, M., Vige, X., Biton, B., Steinberg, R., Francon, D., Alonso, R., Avenet, P., Oury-Donat, F., Perrault, G., Griebel, G., George, P., Soubrie, P., Scatton, B., 2005. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-I SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30, 1963-1985. (Pubitemid 43093498)
10. Duffy, S., Labrie, V., Roder, J.C., 2008. D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology 33, 1004-1018. (Pubitemid 351367543)
11. Egerton, A., Reid, L., McKerchar, C.E., Morris, B.J., Pratt, J.A., 2005. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl.) 179, 77-84. (Pubitemid 40576694)
12. Floresco, S.B., Zhang, Y., Enomoto, T., 2008. Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behav. Brain Res. 204, 396-409.
13. Gozzi, A., Large, C.H., Schwarz, A., Bertani, S., Crestan, V., Bifone, A., 2008. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 33, 1690-1703. (Pubitemid 351684709)
14. Hargreaves, R.J., Rigby, M., Smith, D., Hill, R.G., 1993. Lack of effect of L-687,414 ((+)-Cis-4-methyl-Ha-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose-metabolism and cortical Neuronal Morphology. Brit J. Pharmacol. 110, 36-42.
15. Harich, S., Gross, G., Bespalov, A., 2007. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl.) 192, 511-519. (Pubitemid 46870746)
16. Javitt, D.C., 2008. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiat. 63, 6-8.
17. Kopec, K., Flood, D.G., Gasior, M., McKenna, B.A., Zuvich, E., Schreiber, J., Salvino, J.M., Durkin, J.T., Ator, M.A., Marino, M.J., 2010. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem. Pharmacol. 80, 1407-1417.
18. Krystal, J.H., D'Souza, D.C., Mathalon, D., Perry, E., Belger, A., Hoffman, R., 2003. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl.) 169, 215-233. (Pubitemid 37264943)
19. Labrie, V., Lipina, T., Roder, J.C., 2008. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 200, 217-230.
20. Labrie, V., Roder, J.C., 2010. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 34, 351-372.
21. Le Pen, G., Kew, J., Alberati, D., Borroni, E., Heitz, M.P., Moreau, J.L., 2003. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol. Psychiat. 54, 1162-1170.
22. Lechner, S.M., 2006. Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr. Opin. Pharmacol. 6, 75-81.
23. Lewis, D.A., Gonzalez-Burgos, G., 2008. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33, 141-165. (Pubitemid 350191315)
24. Lipina, T., Labrie, V., Weiner, I., Roder, J., 2005. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl.) 179, 54-67. (Pubitemid 40576692)
25. Marek, G.J., Behl, B., Bespalov, A.Y., Gross, G., Lee, Y., Schoemaker, H., 2010. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol. Pharmacol. 77, 317-326.
26. Martina, M., Gorfinkel, Y., Halman, S., Lowe, J.A., Periyalwar, P., Schmidt, C.J., Bergeron, R., 2004. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 p.ramidal cells by altering extracellular glycine levels. J. Physiol. Lond. 557, 489-500.
27. Mezler, M., Hornberger, W., Mueller, R., Schmidt, M., Amberg, W., Braje, W., Ochse, M., Schoemaker, H., Behl, B., 2008. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol. Pharmacol. 74, 1705-1715.
28. Mohler, H., Boison, D., Singer, P., Feldon, J., Pauly-Evers, M., Yee, B.K., 2011. Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition. Biochem. Pharmacol.. doi:10.1016/j.bcp.2011.02. 003.
29. Morris, B.J., Cochran, S.M., Pratt, J.A., 2005. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5, 101-106.
30. Neeman, G., Blanaru, M., Bloch, B., Kremer, I., Ermilov, M., Javitt, D.C., Heresco-Levy, U., 2005. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry 162, 1738-1740. (Pubitemid 41318246)
31. Nikiforuk, A., Golembiowska, K., Popik, P., 2010. Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur. Neuropsychopharmacol. 20, 37-48.
32. Nikiforuk, A., Popik, P., 2011. Long-lasting cognitive deficit induced by stress is alleviated by acute administration of antidepressants. Psychoneuroendocrinology 36, 28-39.
33. Palmer, C., Ellis, K.A., O'Neill, B.V., Croft, R.J., Leung, S., Oliver, C., Wesnes, K.A., Nathan, P.J., 2008. The cognitive efffects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls. Hum. Psychopharmacol. 23, 151-159.
34. Popik, P., Rygielska, Z., 1999. A partial agonist at strychnine- insensitive glycine sites facilitates spatial learning in aged rats. J. Physiol. Pharmacol. 50, 139-151.
35. Priestley, T., Marshall, G.R., Hill, R.G., Kemp, J.A., 1998. L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective. Brit. J. Pharmacol. 124, 1767-1773.
36. Pussinen, R., Sirvio, J., 1999. Effects of d-cycloserine, a positive modulator of nmethyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J. Psychopharmacol. 13, 171-179. (Pubitemid 29276829)
37. Raiteri, L., Raiteri, M., 2010. Functional 'glial' GLYT1 glycine transporters expressed in neurons. J. Neurochem. 114, 647-653.
38. Roberts, A.C., Robbins, T.W., Everitt, B.J., 1988. The effects of intradimensional and extradimensional shifts on visual discrimination learning in humans and non-human primates. Q. J. Exp. Psychol. B 40, 321-341.
39. Rodefer, J.S., Nguyen, T.N., Karlsson, J.J., Arnt, J., 2008. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT(6) receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33, 2657-2666.
40. Shimazaki, T., Kaku, A., Chaki, S., 2010. d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology 209, 263-270.
41. Singer, P., Boison, D., Mohler, H., Feldon, J., Yee, B.K., 2009a. Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability? Behav. Neurosci. 123, 1012-1027.
42. Singer, P., Feldon, J., Yee, B.K., 2009b. The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (Berl.) 202, 371-384.
43. Song, W.F., Chattipakorn, S.C., McMahon, L.L., 2006. Glycine-gated chloride channels depress synaptic transmission in rat hippocampus. J. Neurophysiol. 95, 2366-2379.
44. Stefani, M.R., Groth, K., Moghaddam, B., 2003. Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav. Neurosci. 117, 728-737.
45. Stefani, M.R., Moghaddam, B., 2010. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur. J. Pharmacol. 639, 26-32.
46. Tortella, F.C., Hill, R.G., 1996. EEG seizure activity and behavioral neurotoxicity produced by (+)-MK801, but not the glycine site antagonist l-687, 414, in the rat. Neuropharmacology 35, 441-448. (Pubitemid 26189388)
47. Tricklebank, M.D., Bristow, L.J., Hutson, P.H., Leeson, P.D., Rowley, M., Saywell, K., Singh, L., Tattersall, F.D., Thorn, L., Williams, B.J., 1994. The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N- methyl-D- aspartate (NMDA) receptor complex. Brit. J. Pharmacol. 113, 729-736.
48. Tsai, G., Ralph-Williams, R.J., Martina, M., Bergeron, R., Berger-Sweeney, J., Dunham, K.S., Jiang, Z.C., Caine, S.B., Coyle, J.T., 2004a. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc. Natl. Acad. Sci. U. S. A. 101, 8485-8490.
49. Tsai, G.C., Lane, H.Y., Yang, P.C., Chong, M.Y., Lange, N., 2004b. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiat. 55, 452-456.
50. Tsai, G.E., Lin, P.Y., 2010. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 16, 522-537.
51. Tunbridge, E.M., Bannerman, D.M., Sharp, T., Harrison, P.J., 2004. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J. Neurosci. 24, 5331-5335. (Pubitemid 38747674)
52. Weiner, I., Arad, M., 2009. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav. Brain Res. 204, 369-386.
53. Yang, S.Y., Hong, C.J., Huang, Y.H., Tsai, S.J., 2010. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats. Neurosci. Lett. 469, 127-130.
54. Yee, B.K., Balic, E., Singer, P., Schwerdel, C., Grampp, T., Gabernet, L., Knuesel, I., Benke, D., Feldon, J., Mohler, H., Boison, D., 2006. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J. Neurosci. 26, 3169-3181.